menu
    • menu
    [{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Group Corporation \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TAK-994","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TAK-994","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sosei Group Corporation

                            Japan arrow
                            Discovery Europe
                            Not Confirmed

                            Sosei Group Corporation

                            Japan arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nxera Pharma's Partner Centessa Initiates Phase 2 Trial of ORX750

                            Details : ORX750 is an investigational, orally administered, highly potent and selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1/2.

                            Product Name : ORX750

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 11, 2024

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Takeda Pharmaceutical

                            Japan arrow
                            Discovery Europe
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TAK-994

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Breakthrough Therapy Designation to Takeda’s Investigational TAK-994

                            Details : Currently, TAK-994 is being studied in an ongoing Phase 2 (TAK-994-1501) study. Data from the completed Phase 2 study will be presented at a future scientific conference after the study’s conclusion.

                            Product Name : TAK-994

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 28, 2021

                            Lead Product(s) : TAK-994

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Takeda Pharmaceutical

                            Japan arrow
                            Discovery Europe
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TAK-994

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Takeda Provides Update on TAK-994 Clinical Program

                            Details : TAK-994, an investigational oral orexin agonist is being analysed to treat excessive daytime sleepiness (EDS) in people with narcolepsy type 1 (NT1).

                            Product Name : TAK-994

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 10, 2021

                            Lead Product(s) : TAK-994

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth